Package Leaflet: Information for the User Cholib 145 mg/40 mg film-coated tabletsfenofibrate/simvastatin
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack:
Cholib contains two different active substances: fenofibrate (belonging to the group of so-called 'fibrates') and simvastatin (belonging to the group of so-called 'statins'). Both are used to reduce the levels of total cholesterol, "bad" cholesterol (LDL), and fatty substances called triglycerides in the blood. Both also increase the levels of "good" cholesterol (HDL).
What should I know about cholesterol and triglycerides?
Cholesterol is one of the different fats present in the blood. Total cholesterol is mainly made up of LDL cholesterol and HDL cholesterol.
LDL cholesterol is known as "bad" cholesterol because it builds up in the walls of the arteries and can form plaques. Over time, the buildup of plaques can block the arteries.
HDL cholesterol is known as "good" cholesterol because it helps prevent "bad" cholesterol from building up in the arteries and protects against heart disease.
Triglycerides are another type of fat present in the blood that can increase the risk of heart problems.
In most people, problems with cholesterol or triglycerides go unnoticed at first. Your doctor can find out your lipid levels with a simple blood test. Visit your doctor regularly to have your lipid levels checked.
Cholib is used in adults with a high risk of problems such as heart attack or stroke who have high levels of two types of fat (triglycerides and LDL cholesterol) in the blood. It is given to reduce triglycerides and increase "good" cholesterol (HDL cholesterol) in patients whose "bad" cholesterol (LDL cholesterol) has already been controlled using only simvastatin with a dose of 40 mg.
You should follow a low-fat diet or take other measures (e.g., exercise, weight loss) during treatment with Cholib.
Do not take Cholib:
Do not take Cholib if any of the above situations apply to you. If in doubt, consult your doctor or pharmacist again.
Warnings and precautions:
Consult your doctor or pharmacist before taking Cholib if:
If any of the above situations apply to you, consult your doctor or pharmacist before taking Cholib. If in doubt, consult your doctor or pharmacist again.
Also, inform your doctor or pharmacist if you experience persistent muscle weakness. Further tests and medication may be necessary to diagnose and treat this problem.
Your doctor will perform a blood test before you start taking Cholib to check how well your liver is working.
Your doctor may also want to perform blood tests to check how well your liver is working after you start taking Cholib.
While taking this medication, your doctor will closely monitor you if you have diabetes or are at risk of developing the disease. You are likely to be at risk of developing diabetes if you have high levels of sugar and fat in your blood, are overweight, and have high blood pressure.
Your doctor may perform a blood test to check your muscles before and after starting treatment.
Children and adolescents
Cholib should not be given to children or adolescents (under 18 years old).
Taking Cholib with other medicines:
It is especially important that you inform your doctor or pharmacist if you are taking, have recently taken, or might take other medicines. This also applies to medicines without a prescription, including herbal medicines.
Inform your doctor or pharmacist if you are taking any of the following medications:
organs)
(medications used in HIV and AIDS infection)
or elbasvir, grazoprevir, glecaprevir, or pibrentasvir (used to treat hepatitis C virus infection)
or erythromycin, clarithromycin, or telithromycin (medications for bacterial infections) or nefazodone (a medication for depression)
or amiodarone (a medication for heart rhythm disorders) or verapamil (a medication used for high blood pressure, chest pain associated with heart disease, and other heart conditions)
or a fibrate (e.g., fenofibrate, gemfibrozil)
Do not take Cholib if any of the above situations apply to you. If in doubt, consult your doctor or pharmacist again.
In particular, inform your doctor or pharmacist if you are taking any of the following medications (taking Cholib with any of these medications may increase the risk of muscle problems):
Do not take fusidic acid (an antibiotic) while using this medication.
Apart from the medications mentioned above, inform your doctor or pharmacist if you are taking, have recently taken, or might take any of the following medications:
If any of the above situations apply to you, consult your doctor or pharmacist before taking Cholib. If in doubt, consult your doctor or pharmacist again.
Cholib with food and drinks
Grapefruit juice contains one or more components that alter the way the body uses Cholib. Do not take grapefruit juice with Cholib, as it may increase your risk of muscle problems.
Pregnancy and breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines:
Cholib is not expected to affect your ability to drive or use tools or machines. However, you should be aware that some people may feel dizzy after taking Cholib.
Important information about some of the ingredients of Cholib
Cholib contains types of sugars called lactose and sucrose. If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medication.
Cholib contains soy lecithin. If you are allergic to peanuts, soy, or peanut oil, do not use Cholib.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor.
In case of doubt, consult your doctor or pharmacist again.
Your doctor will determine the appropriate dose for you based on your condition, current treatment, and personal risk factors.
The usual dose is one tablet per day.
You can take Cholib with or without food.
The tablets should be swallowed with a glass of water.
The tablets should not be crushed or chewed.
You should follow a low-fat diet or take other measures (e.g., exercise, weight loss) while taking Cholib.
If you take more Cholib than you should
If you have taken more Cholib than you should or if someone else has taken your medicine, inform your doctor or pharmacist or contact the nearest hospital.
If you forget to take Cholib
Do not take a double dose to make up for forgotten tablets. Take the next tablet at the usual time the next day. If you are concerned, consult your doctor or pharmacist.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Some patients have experienced the following serious adverse effects while taking fenofibrate or simvastatin (both active ingredients of Cholib):
If you experience any of the serious adverse effects listed above, stop taking Cholib and inform your doctor immediately or go to the emergency department of the nearest hospital; you may need urgent medical treatment.
Some patients have experienced the following adverse effects while taking Cholib, fenofibrate, or simvastatin:
Very frequent adverse effects (may affect more than 1 in 10 people):
Frequent adverse effects (may affect up to 1 in 10 people):
Uncommon adverse effects (may affect up to 1 in 100 people):
Rare adverse effects (may affect up to 1 in 1,000 people):
Very rare adverse effects (may affect up to 1 in 10,000 people):
The following adverse effects have also been reported, but their frequency cannot be estimated from the available data (frequency not known):
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report it directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Cholib after the expiration date that appears on the box and blister after CAD.
The expiration date is the last day of the month indicated.
Store below 30 °C.
Medicines should not be thrown away through wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Composition of Cholib
The active ingredients are fenofibrate and simvastatin. Each tablet contains 145 mg of fenofibrate and 40 mg of simvastatin.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, i.e., it is essentially "sodium-free".
The other ingredients are:
Core of the tablet:
Butylhydroxyanisole (E320), lactose monohydrate, sodium lauryl sulfate, pregelatinized corn starch, sodium docusate, sucrose, citric acid monohydrate (E330), hypromellose (E464), crospovidone (E1202), magnesium stearate (E572), silicified microcrystalline cellulose (composed of microcrystalline cellulose and anhydrous colloidal silicon dioxide), ascorbic acid (E300).
Coating:
Partially hydrolyzed polyvinyl alcohol (E1203), titanium dioxide (E171), talc (E553b), soybean lecithin (E322), xanthan gum (E415), red iron oxide (E172).
Appearance of Cholib and Package Contents
Tablet coated with a film, oval, biconvex, brick-red in color, with the inscription 145/40 on one side. The diameter is approximately 19.3 x 9.3 mm and the weight of the tablet is approximately 840 mg.
The tablets are presented in cardboard boxes with blisters containing 10, 30, or 90 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Mylan IRE Healthcare Ltd, Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13 – Ireland.
Manufacturer:
Mylan Laboratories SAS, Route de Belleville - Lieu-dit Maillard, 01400 Châtillon-sur-Chalaronne - France.
Mylan Hungary Kft., Mylan utca 1, Komárom 2900, Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorization holder.
Belgium | Ireland | Norway |
Mylan EPD | Mylan IRE Healthcare Ltd | Mylan Healthcare Norge AS |
Tel: + 32 2 658 61 00 | Tel: +44 (0) 1707 853000 | Tel: + 47 66 75 33 00 |
Bulgaria | Iceland | Austria |
Mylan Bulgaria EOOD | Icepharma hf. | Mylan Österreich GmbH |
Tel: + 359 2 4455 400 | Tel: +354 540 8000 | Tel: +43 1 89124-0 |
Czech Republic | Italy | Poland |
Mylan Healthcare CZ s.r.o. | Mylan Italia S.r.l. | Mylan Healthcare Sp. z o.o. |
Tel: +420 222 004 400 | Tel: + 39 (0) 2 61246921 | Tel: +48 22 546 64 00 |
Denmark | Cyprus | Portugal |
Mylan Denmark ApS | Varnavas Hadjipanayis Ltd | BGP Products, Unipessoal, Lda. |
Tel: + 45 28 11 69 32 | Tel: +357 22207700 | Tel: +351 214 127 256 |
Germany | Latvia | Romania |
Mylan Healthcare GmbH | Mylan Healthcare SI | BGP Products S.R.L. |
Tel: +49 511 4754 3400 | Tel: + 371 67 605 580 | Tel: +40 372 579 000 |
Estonia | Lithuania | Slovenia |
BGP Products Switzerland GmbH | Mylan Healthcare UAB | Mylan Healthcare d.o.o. |
Estonian branch | Tel: +370 52 051 288 | Tel: + 386 (0)123 63 180 |
Tel: + 372 6363052 | ||
Greece | Luxembourg | Slovak Republic |
BGP PRODUCTS Μ.Ε.Π.Ε. | Mylan EPD sprl-bvba | BGP Products s.r.o. |
Tel: +30 210 9891 777 | Tel/Tél: + 32 2 658 6100 | Tel: +421 2 40 20 38 00 |
Spain | Hungary | Finland |
Mylan pharmaceuticals S.L. | Mylan EPD Kft | Mylan Finland Oy |
Tel: +34 91 669 93 00 | Tel: +36 1 465 2100 | Tel: +358 20 720 9555 |
France | Malta | Sweden |
Mylan Medical SAS | V.J. Salomone Pharma Limited | BGP Products AB |
Tel: + 33 (0)1 56 64 10 70 | Tel: +356-22-98 31 43 | Tel: +46 8 555 227 07 |
Croatia | Netherlands | United Kingdom |
Mylan Hrvatska d.o.o. | Mylan Healthcare B.V. | Mylan Products Ltd |
Tel: + 385 (0)1 2350 599 | Tel: +31 (0)20 426 33 00 | Tel: +44 (0) 170 785 3000 |
Date of the Last Revision of this Prospectus:
Detailed information about this medicine is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu.